(UroToday.com) The 2023 ASCO annual meeting included a kidney cancer session, featuring a presentation by Dr. Brian Rini discussing the 5-year analysis of KEYNOTE-426, assessing pembrolizumab + ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results